Takeda Pharmaceutical Company Limited (TAK)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Takeda Pharmaceutical Company Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Takeda Pharmaceutical Company Limited (TAK) has returned 18.79% so far this year and 27.35% over the past 12 months. Over the last ten years, TAK has returned 1.65% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Oct 27, 2008, TAK's average daily return is +0.02%, while the average monthly return is +0.41%. At this rate, your investment would double in approximately 14.1 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jan 2015 with a return of +20.9%, while the worst month was May 2013 at -18.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, TAK closed higher 51% of trading days. The best single day was Mar 10, 2009 with a return of +9.5%, while the worst single day was Mar 12, 2020 at -12.0%.

Takeda Pharmaceutical Company Limited has an annualized alpha of -0.89%, beta of 0.46, and R² of 0.14 versus S&P 500 Index. Calculated based on daily prices since October 28, 2008.

• This stock participated in 50.58% of S&P 500 Index downside but only 30.77% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.46 may look defensive, but with R² of 0.14 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.14 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TAK ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and compare them to a chosen benchmark (S&P 500 Index).

Takeda Pharmaceutical Company Limited provided a 1.74% dividend yield over the last twelve months, with an annual payout of $0.32 per share.

The table displays the monthly dividend distributions for Takeda Pharmaceutical Company Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Takeda Pharmaceutical Company Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Takeda Pharmaceutical Company Limited was 54.25%, occurring on Mar 18, 2020. The portfolio has not yet recovered.

The current Takeda Pharmaceutical Company Limited drawdown is 18.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Takeda Pharmaceutical Company Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Takeda Pharmaceutical Company Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.